Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative safety and effectiveness of apixaban versus warfarin in antiphospholipid syndrome with chronic kidney disease: A real-world propensity-matched cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFayaz KhanZAZuhair Alam

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows apixaban lowers major bleeding and mortality in patients with antiphospholipid syndrome and chronic kidney disease, suggesting a safer alternative to warfarin.

Key Points

  • This research evaluates the safety and effectiveness of apixaban compared to warfarin in patients with antiphospholipid syndrome and chronic kidney disease.
  • Conducted a retrospective cohort study using TriNetX US Collaborative Network.
  • Identified adults with antiphospholipid syndrome and stage 3–5 chronic kidney disease starting apixaban or warfarin.
  • Applied propensity score matching (1:1) based on demographics and comorbidities, analyzing outcomes with Kaplan-Meier.
  • Compared outcomes, reporting hazard ratios and log-rank p-values.
  • Apixaban associated with lower risk of major bleeding (HR 0.46, p=0.005) and intracranial hemorrhage (HR 0.14, p=0.030).
  • No significant differences in rates of gastrointestinal bleeding, thrombotic events including deep vein thrombosis and ischemic stroke.
  • All-cause mortality was significantly lower in the apixaban group (HR 0.51, p=0.000).
  • Outcomes related to healthcare utilization showed no significant differences between the two groups.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d04ahttps://doi.org/10.1182/blood-2025-318
View Full Paper
Ask AI
Bookmark
Share